Literature DB >> 21414268

The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis.

Quarraisha Abdool Karim1, Salim S Abdool Karim, Cheryl Baxter, Gerald Friedland, Tanuja Gengiah, Andrew Gray, Anneke Grobler, Kogileum Naidoo, Nesri Padayatchi, Wafaa El-Sadr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21414268     DOI： 10.7196/samj.4621

Source DB:  PubMed          Journal:  S Afr Med J


× No keyword cloud information.
  3 in total

1.  Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.

Authors:  S H Han; J Zhou; M P Lee; H Zhao; Y-M A Chen; N Kumarasamy; S Pujari; C Lee; S F S Omar; R Ditangco; N Phanuphak; S Kiertiburanakul; R Chaiwarith; T P Merati; E Yunihastuti; J Tanuma; V Saphonn; A H Sohn; J Y Choi
Journal:  HIV Med       Date:  2013-08-28       Impact factor: 3.180

2.  Predictors and Timing of ATT Initiation among HIV-TB Patients at ART Centers of Karnataka, India: Two Year Follow-Up.

Authors:  Suresh Shastri; Sharath Burugina Nagaraja; Jaya Prasad Tripathy; Srinath Satyanarayana; Bharat Bhushan Rewari
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

3.  Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.

Authors:  Nilesh B Bhatt; Elisabeth Baudin; Bindiya Meggi; Carlota da Silva; Aurélie Barrail-Tran; Valérie Furlan; Beatriz Grinsztejn; Maryline Bonnet; Anne-Marie Taburet
Journal:  J Antimicrob Chemother       Date:  2014-09-18       Impact factor: 5.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.